JNJ 63823539

Drug Profile

JNJ 63823539

Alternative Names: JNJ63823539

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Covagen
  • Developer Cilag GmbH International; Covagen
  • Class Bispecific antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 07 Apr 2017 Phase-I clinical trials in Rheumatoid arthritis in Switzerland (SC) before March 2017 )
  • 15 Mar 2017 Phase I clinical trials in Rheumatoid arthritis in Switzerland (IV, infusion) before March 2017
  • 15 Mar 2017 Pharmacokinetics and immunogenicity data from a phase I trial in Rheumatoid arthritis released by Covagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top